Children and adolescents treated for solid brain tumors with chemotherapy and craniospinal irradiation are at increased risk of metabolic changes development. Current follow-up guidelines for cancer survivors recommend to monitor fasting glucose and HbA1 levels for diabetes/impaired glucose tolerance screening in these patients. The aim of our study was to evaluate metabolic changes in children treated for medulloblastoma with oral glucose tolerance test (OGTT). We examined 63 patients (40 males/23 females). Patients had a median age (range) of 11.3 (5.517.9) years. They were treated for medulloblastoma when aged 6.8 (1.216.2) years. The outcome measures were: BMI SDS, fasting glucose, HbA1c, OGTT (0, 30, 60, 90 and 120 min). We identified 4 patients with impaired glucose tolerance (120-min glucose ≥ 7.8 mmol/l). All patients with impaired glucose tolerance had normal values of fasting glucose (4.3 ÷ 5.04 mmol/l) and HbA1c (4.8 ÷ 5.8%). All these patients had normal BMI SDS (0.06 ÷ −1.7).
Conclusion: Children and adolescents treated for solid brain tumors by chemotherapy and craniospinal irradiation should be screened for glucose tolerance impairment by OGTT regardless of fasting glucose, HbA1c and BMI SDS values.
18 - 21 May 2019
European Society of Endocrinology